Neurosoft Biolelectronics

Executive Summary

Neurosoft Biolelectronics, headquartered in Lausanne, Switzerland, is a deeptech company developing ultra-soft, minimally invasive brain-computer interfaces (BCI) that aim to reduce complications such as scar tissue formation and subdural hematomas. Founded in 2019, the company combines its proprietary soft electrode technology with artificial intelligence for enhanced neural data analysis and treatment algorithms. This approach could address key limitations of existing BCIs, including invasive surgical risks and chronic inflammatory responses, potentially enabling safer long-term implantation. Neurosoft's vision aligns with the growing demand for neurotechnology in therapeutic areas such as paralysis, epilepsy, and neurodegenerative diseases. While the company remains in a private, early-stage development phase with no disclosed funding rounds, its technological differentiation and focus on biocompatibility position it as an emerging player in the BCI landscape. The absence of clinical data or regulatory milestones to date underscores both the high risk and the transformative potential if the technology succeeds. Continued progress in preclinical studies and strategic partnerships will be critical to advancing toward clinical translation and capturing market interest.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial results20% success
• Q2 2027Regulatory submission for CE marking or FDA breakthrough device designation30% success
• H2 2026Partnership or licensing deal with a major neurology research center40% success